MCID: MLG074
MIFTS: 46

Malignant Mesenchymoma

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Malignant Mesenchymoma

MalaCards integrated aliases for Malignant Mesenchymoma:

Name: Malignant Mesenchymoma 12 50 14
Malignant Mesenchymal Tumor 50 42 69
Rat Malignant Renal Mesenchymal Tumor 69
Mesenchymoma, Malignant 12
Sarcoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5758
MeSH 42 C535700
NCIt 47 C4268
SNOMED-CT 64 89623007
UMLS 69 C0334492

Summaries for Malignant Mesenchymoma

MalaCards based summary : Malignant Mesenchymoma, also known as malignant mesenchymal tumor, is related to liposarcoma and liposarcoma of bone. An important gene associated with Malignant Mesenchymoma is MB (Myoglobin), and among its related pathways/superpathways are Pathways in cancer and Chks in Checkpoint Regulation. The drugs Carboplatin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and heart, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cardiovascular system

Related Diseases for Malignant Mesenchymoma

Diseases in the Mesenchymoma family:

Benign Mesenchymoma Malignant Mesenchymoma
Adult Malignant Mesenchymoma

Diseases related to Malignant Mesenchymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 160)
id Related Disease Score Top Affiliating Genes
1 liposarcoma 30.9 EWSR1 MDM2
2 liposarcoma of bone 30.0 EWSR1 WT1
3 childhood malignant mesenchymoma 11.9
4 adult malignant mesenchymoma 11.9
5 gallbladder sarcoma 10.9
6 bile duct rhabdomyosarcoma 10.8 KIT MYOD1
7 gigantism 10.8 DES MB
8 marfanoid habitus-inguinal hernia-advanced bone age syndrome 10.8 DES KIT
9 spleen cancer 10.8 DES MB MYOD1
10 ceroid lipofuscinosis, neuronal, 9 10.8 ETV6 NTRK3
11 mucinous ovarian cystadenoma 10.8 DES MB MYOD1
12 omphalocele 10.8 DES MYOD1
13 rectal neoplasm 10.7 DES KIT MB
14 mesenchymoma 10.7
15 intracystic papillary adenoma 10.7 ETV6 NTRK3
16 skin lipoma 10.7 CDK4 DES MDM2
17 coronary restenosis 10.7 DES MDM2 NTRK3
18 median neuropathy 10.7 CDK4 MB MDM2
19 46xy sex reversal 5 10.7 DES MB MYOD1
20 neurofibroma of the esophagus 10.7 CDK4 DES MDM2
21 coronary aneurysm 10.7 CDK4 GALNT3 MDM2
22 glomus tumor 10.6 KIT NCAM1
23 sarcosinemia 10.6 CDK4 DES MDM2
24 follicular infundibulum tumor 10.6 DES ETV6 NTRK3
25 transitional cell carcinoma 10.6 DES MB MDM2 MYOD1
26 cowper gland carcinoma 10.6 MB TP53
27 cerebral arterial disease 10.6 ETV6 NTRK3
28 embryonal extrahepatic bile duct rhabdomyosarcoma 10.6 MB MYOD1 TP53
29 vulvar liposarcoma 10.6 MB MDM2 TP53
30 epidural neoplasm 10.6 CDK4 MDM2
31 fallopian tube squamous cell carcinoma 10.5 KIT MB TP53
32 goiter, multinodular 1, with or without sertoli-leydig cell tumors 10.5 DES MB TP53
33 reactive arthritis 10.5 CDK4 MDM2
34 fibrosarcoma of bone 10.5 EWSR1 KIT MYOD1
35 epithelioid trophoblastic tumor 10.5 KIT WT1
36 biliary dyskinesia 10.5 MB MDM2 TP53
37 klatskin's tumor 10.5 CDK4 ETV6 NTRK3
38 hypersensitivity reaction type iii disease 10.5 KIT MB TP53
39 rnase t2-deficient leukoencephalopathy 10.5 CDK4 MDM2 TP53
40 chondroid chordoma 10.5 EWSR1 MB NCAM1
41 anus leiomyoma 10.5 CALD1 KIT
42 phagocyte bactericidal dysfunction 10.5 MB MYOG
43 breast epithelioid hemangioma 10.5 CDK4 MDM2 TP53
44 exertional headache 10.5 CDK4 EWSR1 KIT
45 thymus lipoma 10.4 NCAM1 WT1
46 mannose-binding lectin protein deficiency 10.4 DES KIT
47 liver angiosarcoma 10.4 DES KIT WT1
48 cystic lymphangioma 10.4 CDK4 MDM2 TP53
49 brain stem infarction 10.4 CALD1 KIT MDM2
50 lung leiomyosarcoma 10.4 KIT MDM2 WT1

Graphical network of the top 20 diseases related to Malignant Mesenchymoma:



Diseases related to Malignant Mesenchymoma

Symptoms & Phenotypes for Malignant Mesenchymoma

GenomeRNAi Phenotypes related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 SSX2B WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.84 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.84 WT1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.84 NTRK3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.84 NTRK3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.84 SSX2B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.84 NTRK3 WT1 KIT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.84 KIT
9 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.84 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.84 SSX2B WT1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.84 WT1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 NTRK3 SSX2B WT1 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.84 WT1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.84 NTRK3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.84 NTRK3 KIT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.84 WT1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.84 SSX2B WT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.84 SSX2B
19 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.84 SSX2B
20 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 NTRK3 WT1 KIT
21 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.84 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.84 KIT

MGI Mouse Phenotypes related to Malignant Mesenchymoma:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.37 CDK4 CDKN1A DES ETV6 GALNT3 KIT
2 growth/size/body region MP:0005378 10.36 UCHL1 WT1 CDK4 CDKN1A ETV6 GALNT3
3 homeostasis/metabolism MP:0005376 10.35 CDK4 CDKN1A DES ETV6 FHIT GALNT3
4 mortality/aging MP:0010768 10.28 CDK4 CDKN1A DES ETV6 FHIT KIT
5 cellular MP:0005384 10.25 CDK4 CDKN1A DES ETV6 KIT MB
6 digestive/alimentary MP:0005381 10.24 MDM2 PNLIP TP53 UCHL1 CDK4 CDKN1A
7 hematopoietic system MP:0005397 10.24 MB MDM2 TP53 UCHL1 WT1 CDK4
8 embryo MP:0005380 10.18 CDK4 CDKN1A ETV6 KIT MB MDM2
9 integument MP:0010771 10.16 CDK4 CDKN1A ETV6 FHIT GALNT3 KIT
10 muscle MP:0005369 10.07 CDK4 CDKN1A DES KIT MB MDM2
11 liver/biliary system MP:0005370 10.03 CDK4 CDKN1A KIT MDM2 PNLIP TP53
12 neoplasm MP:0002006 9.97 CDK4 CDKN1A ETV6 FHIT KIT MDM2
13 no phenotypic analysis MP:0003012 9.91 CDKN1A ETV6 KIT MDM2 MYOD1 MYOG
14 normal MP:0002873 9.81 CDK4 ETV6 KIT MDM2 MYOD1 MYOG
15 renal/urinary system MP:0005367 9.56 MDM2 TP53 UCHL1 WT1 CDK4 CDKN1A
16 respiratory system MP:0005388 9.28 MB MYOD1 MYOG NTRK3 TP53 UCHL1

Drugs & Therapeutics for Malignant Mesenchymoma

Drugs for Malignant Mesenchymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
6
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
7
Morphine Approved, Investigational Phase 3 57-27-2 5288826
8
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700
9
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
10
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
11
Lenograstim Approved Phase 3,Phase 2 135968-09-1
12
Irinotecan Approved, Investigational Phase 3,Phase 2 97682-44-5, 100286-90-6 60838
13
Mechlorethamine Approved Phase 3,Phase 1 51-75-2 4033
14
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
15
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
16
Mesna Approved Phase 3 3375-50-6 598
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
18
Camptothecin Experimental Phase 3,Phase 2 7689-03-4
19 Alkylating Agents Phase 3,Phase 2,Phase 1
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
21 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
22 Anti-Infective Agents Phase 3,Phase 2
23 Antimitotic Agents Phase 3,Phase 2
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
25 Antirheumatic Agents Phase 3,Phase 2
26 Etoposide phosphate Phase 3,Phase 2
27 Immunosuppressive Agents Phase 3,Phase 2
28 Isophosphamide mustard Phase 3,Phase 2,Phase 1
29 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
30 topoisomerase I inhibitors Phase 3,Phase 2
31 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
32 Adjuvants, Immunologic Phase 3,Phase 1
33
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
34
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
35
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
36
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
37
Gemcitabine Approved Phase 2 95058-81-4 60750
38 Imatinib Mesylate Phase 2,Phase 1 123596
39 Protein Kinase Inhibitors Phase 2,Phase 1
40 Angiogenesis Inhibitors Phase 2,Phase 1
41 Angiogenesis Modulating Agents Phase 2,Phase 1
42 Antimetabolites Phase 2
43 Antimetabolites, Antineoplastic Phase 2
44 Antiviral Agents Phase 2
45 Protective Agents Phase 2
46 razoxane Phase 2
47 Antibodies Phase 1
48 Antibodies, Monoclonal Phase 1
49 Immunoglobulins Phase 1
50 Interleukin-12 Phase 1

Interventional clinical trials:

(show all 32)

id Name Status NCT ID Phase Drugs
1 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
2 Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma Completed NCT00003958 Phase 3 vincristine sulfate;cyclophosphamide;topotecan hydrochloride
3 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
4 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00002995 Phase 3 cyclophosphamide;vincristine sulfate
6 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
7 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
9 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
10 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Active, not recruiting NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
11 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
12 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
13 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
14 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
15 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
16 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma Completed NCT00003955 Phase 2 cyclophosphamide;irinotecan hydrochloride;vincristine sulfate
17 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
18 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
19 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
20 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
21 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
22 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
23 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
24 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
25 Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma Active, not recruiting NCT00077285 Phase 2 carboplatin;cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
26 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
27 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
28 Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00030784 Phase 1 ifosfamide;pegylated liposomal doxorubicin hydrochloride
29 NHS-IL12 for Solid Tumors Recruiting NCT01417546 Phase 1 NHS-IL-12
30 Tissue Sample Collection From Patients With Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet Treated on Clinial Trial CRUK-VORTEX Unknown status NCT00900211
31 Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas Completed NCT01567046
32 Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma Withdrawn NCT00334984 glutamine

Search NIH Clinical Center for Malignant Mesenchymoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: malignant mesenchymal tumor

Genetic Tests for Malignant Mesenchymoma

Anatomical Context for Malignant Mesenchymoma

MalaCards organs/tissues related to Malignant Mesenchymoma:

39
Bone, Lung, Heart, Kidney, Liver, Prostate, Breast

Publications for Malignant Mesenchymoma

Articles related to Malignant Mesenchymoma:

(show top 50) (show all 121)
id Title Authors Year
1
Primary malignant mesenchymoma of bladder: Case report and review of the literature. ( 28796040 )
2017
2
Critical reappraisal of primary osseous composite sarcoma (malignant mesenchymoma) - analysis of four cases and literature review. ( 27102568 )
2016
3
Malignant mesenchymoma with widespread metastasis including bone marrow involvement in a dog. ( 25132008 )
2014
4
Diagnosis and treatment considerations in a case of malignant mesenchymoma in an African fur seal (Arctocephalus pusillus). ( 23805568 )
2013
5
Combined cutaneous sarcoma: pleomorphic liposarcoma and conventional osteosarcoma-the so-called malignant mesenchymoma. ( 23082265 )
2012
6
Malignant mesenchymoma of the heart base in a dog with infiltration of the pericardium and metastasis to the lung. ( 22516086 )
2012
7
Metastatic leiomyosarcoma of the uterus with heterologous differentiation to malignant mesenchymoma. ( 22833086 )
2012
8
Malignant mesenchymoma in the nasal cavity of a bull. ( 21306728 )
2011
9
Malignant mesenchymoma surrounding the esophageal hiatus. ( 20103193 )
2010
10
An intra-abdominal malignant mesenchymoma associated with nonabsorbable sutures in a ferret (Mustela putorius furo). ( 20224105 )
2010
11
Malignant mesenchymoma of the thyroid: case report and literature review. ( 20572598 )
2010
12
Surgical case of giant malignant mesenchymoma in the posterior mediastinum that recurred in the bilateral mediastinum. ( 18781043 )
2008
13
Left atrial malignant mesenchymoma--emergency resection and mitral replacement. ( 17664193 )
2007
14
Uterine malignant mesenchymoma, arising in a leiomyoma, with pulmonary metastases. ( 17257144 )
2007
15
Intermandibular malignant mesenchymoma in a crossbreed dog. ( 16961475 )
2006
16
Malignant mesenchymoma arising from a uterine leiomyoma in the menopause. ( 15581987 )
2004
17
Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone. ( 15792374 )
2004
18
Primary osteochondrorhabdomyosarcoma (malignant mesenchymoma) of the fibula: a rare tumour in an unusual site -- case report and review of the literature. ( 15601312 )
2004
19
Prognostic factors in the so-called malignant mesenchymoma: a clinicopathological and immunohistochemical analysis. ( 12792727 )
2003
20
Malignant mesenchymoma of the pleura. ( 17670075 )
2003
21
Malignant mesenchymoma of the orbit: case report and review of the literature. ( 12578773 )
2003
22
Retroperitoneal malignant mesenchymoma: a case of mesenchymal mixed tumor with osteosarcoma, leiomyosarcoma, liposarcoma and fibrosarcoma. ( 12514345 )
2002
23
Radical resection of a malignant mesenchymoma with hypogastric artery transposition. ( 12210036 )
2002
24
Primary malignant mesenchymoma of the heart. ( 11788281 )
2002
25
Malignant mesenchymoma of the uterus, arising in a leiomyoma. ( 11903599 )
2002
26
Giant malignant mesenchymoma of the spermatic cord with bidirectional differentiation. ( 11441285 )
2001
27
Malignant mesenchymoma of the lower leg. ( 11684725 )
2001
28
Ring chromosomes in a malignant mesenchymoma. ( 10087943 )
1999
29
Retroperitoneal malignant mesenchymoma: imaging findings in five cases. ( 9933683 )
1999
30
Malignant mesenchymoma associated with an unusual vasoinvasive metastasis in a dog. ( 9657162 )
1998
31
Malignant mesenchymoma arising in an incisional scar of the abdominal wall. ( 9800981 )
1998
32
Primary left atrial malignant mesenchymoma: a case report. ( 9607271 )
1998
33
Radiation-induced malignant mesenchymoma of the chest wall following treatment for breast cancer. ( 9166083 )
1997
34
Maxillary malignant mesenchymoma and massive fibrous dysplasia. ( 9006514 )
1997
35
Primary osteorhabdomyosarcoma (malignant mesenchymoma) of bone: a case report and review of the literature. ( 9346186 )
1997
36
Malignant mesenchymoma of the spermatic cord with a brief review of the literature. ( 9179703 )
1997
37
Malignant mesenchymoma. ( 8630953 )
1996
38
Malignant mesenchymoma arising from the prostate in Gardner's syndrome. ( 8776827 )
1996
39
Clinical image. Malignant mesenchymoma of the buttock. ( 8933808 )
1996
40
Malignant mesenchymoma of the pleura. ( 8638184 )
1996
41
Dedifferentiated cystic nephroma with malignant mesenchymoma as the dedifferentiated component. ( 9025898 )
1996
42
Malignant mesenchymoma of the thigh. ( 7644947 )
1995
43
Malignant mesenchymoma as a primary urinary bladder tumour. ( 7767934 )
1995
44
Primary malignant mesenchymoma of bone: case report, literature review, and distinction of this entity from mesenchymal and dedifferentiated chondrosarcoma. ( 7644944 )
1995
45
Panuveal malignant mesenchymoma. ( 7668945 )
1995
46
CT findings of retroperitoneal malignant mesenchymoma. ( 8161915 )
1994
47
Retroperitoneal malignant mesenchymoma: a case report. ( 7614386 )
1994
48
A case of retroperitoneal malignant mesenchymoma. ( 7834083 )
1994
49
Malignant mesenchymoma of the prostate: immunohistochemical and ultrastructural observations. ( 7941044 )
1994
50
Malignant mesenchymoma of the spermatic cord. ( 8088727 )
1994

Variations for Malignant Mesenchymoma

Expression for Malignant Mesenchymoma

Search GEO for disease gene expression data for Malignant Mesenchymoma.

Pathways for Malignant Mesenchymoma

Pathways related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

(show all 29)
id Super pathways Score Top Affiliating Genes
1 12.57 CDK4 CDKN1A KIT MDM2 TP53
2
Show member pathways
12.55 CDK4 CDKN1A MDM2 TP53 UCHL1
3
Show member pathways
12.29 CDK4 CDKN1A MDM2 TP53
4 12.28 CDK4 CDKN1A MDM2 TP53
5 12.2 CDK4 CDKN1A MDM2 TP53
6
Show member pathways
12.16 CDK4 CDKN1A MDM2 TP53
7
Show member pathways
12.12 CDK4 CDKN1A MDM2 NTRK3 TP53
8 11.96 CDK4 CDKN1A MDM2 TP53
9 11.8 CDK4 CDKN1A MDM2 TP53
10
Show member pathways
11.76 CDKN1A MDM2 TP53
11 11.72 CDKN1A MDM2 TP53
12 11.7 CDKN1A KIT MYOD1
13 11.67 CDK4 CDKN1A MYOD1
14 11.66 CDK4 CDKN1A FHIT TP53
15 11.64 CDKN1A MDM2 TP53
16 11.61 CDK4 CDKN1A MDM2 TP53
17 11.58 KIT NTRK3 TP53
18 11.49 CDKN1A MDM2 MYOD1
19 11.49 CDK4 CDKN1A MDM2 TP53
20 11.44 CDKN1A TP53 UCHL1
21 11.42 CDKN1A ETV6 EWSR1 MDM2 SSX2B TP53
22 11.34 DES KIT MYOD1 MYOG NCAM1
23 11.3 CDKN1A MYOD1 TP53
24 11.22 CDK4 CDKN1A MDM2 TP53
25 11.18 CDK4 CDKN1A TP53
26 11.16 CDK4 MDM2 TP53
27 11.1 CDK4 CDKN1A MDM2 TP53
28
Show member pathways
10.92 CDKN1A MDM2 TP53
29 10.72 CDKN1A TP53

GO Terms for Malignant Mesenchymoma

Cellular components related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.73 CALD1 CDK4 CDKN1A DES ETV6 FHIT
2 nucleolus GO:0005730 9.17 CDK4 CDKN1A ETV6 EWSR1 MDM2 TP53

Biological processes related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.71 MB MDM2 NTRK3 WT1
2 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.5 CDKN1A MDM2 TP53
3 myotube differentiation GO:0014902 9.46 MYOD1 MYOG
4 replicative senescence GO:0090399 9.43 CDKN1A TP53
5 positive regulation of skeletal muscle fiber development GO:0048743 9.37 MYOD1 MYOG
6 muscle cell fate commitment GO:0042693 9.26 MYOD1 MYOG
7 signal transduction by p53 class mediator GO:0072331 9.16 CDKN1A TP53
8 cellular response to actinomycin D GO:0072717 8.96 MDM2 TP53
9 cellular response to gamma radiation GO:0071480 8.8 CDKN1A MDM2 TP53

Molecular functions related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.46 ETV6 MYOD1 MYOG TP53
2 p53 binding GO:0002039 9.13 MDM2 NTRK3 TP53
3 ubiquitin protein ligase binding GO:0031625 9.1 CDKN1A FHIT MDM2 MYOD1 TP53 UCHL1
4 protein binding GO:0005515 10.16 CALD1 CDK4 CDKN1A DES ETV6 EWSR1

Sources for Malignant Mesenchymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....